Tango Therapeutics President, R&D Crystal Adam disposes of USD 734,514 common shares
TNGX•Insider stake reduced through option exercise and sale
Crystal Adam, President, R&D at Tango Therapeutics, cut her stake to 115,743 shares in transactions dated Aug. 3, 2026.
- Exercised stock options for 27,000 shares at $5.2.
- Sold 27,000 shares at weighted average prices of $26.79 and $27.35.
